Stock Information
symbol line chart

BDXBecton Dickinson & Co.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Thomas E. Polen

Location

New Jersey, USA

Exchange

NYSE

Website

https://bd.com

Summary

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public.

Company Info

CEO

Thomas E. Polen

Location

New Jersey, USA

Exchange

NYSE

Website

https://bd.com

Summary

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public.

AI Insights for BDX
2 min read

Quick Summary

Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Its main customers include healthcare institutions, physicians, life science researchers, clinical laboratories, and pharmaceutical companies. BD operates through key segments, primarily BD Medical and BD Life Sciences, providing essential equipment for hospitals, research labs, and therapeutic applications worldwide. The company’s offerings are deeply integrated into clinical workflows, supporting patient care, diagnostics, and research. With a robust international presence, BD aims to advance healthcare delivery and support better health outcomes globally.

The Bull Case

  • Becton Dickinson’s primary strengths lie in its extensive global footprint, robust recurring revenue base, and a diversified product portfolio serving critical healthcare needs.
  • The company benefits from a longstanding reputation as a trusted supplier to hospitals, clinics, and laboratories, reinforcing strong customer relationships and brand loyalty.
  • Its technological leadership in medical devices, particularly in IV access and diagnostic testing, provides a competitive edge.
  • Efficient cost management and improving operating margins contribute to solid financial health.
  • Ongoing investment in research and partnerships further bolster BD’s capacity for sustained innovation and resilience in a rapidly evolving industry.

The Bear Case

  • BDX faces challenges related to lower relative growth rates compared to industry peers, which has been a concern for investors following weak or cautious guidance.
  • The share price has been under pressure, reflecting market disappointment with missed earnings or conservative outlooks.
  • Premium valuation, as indicated by its high P/E ratio, exposes BD to downside risk if performance expectations are not met.
  • Additionally, dependence on the performance of specific segments, like BD Medical, can create vulnerability if market demand shifts.
  • The company’s size and complexity may also slow adaptation to fast-changing industry dynamics.

Key Risks

  • Key risks for Becton Dickinson include intensifying competition from both established players and innovative upstarts, which may erode market share or compress margins.
  • Macroeconomic headwinds, such as inflation, supply chain disruptions, and global economic slowdowns, threaten profitability.
  • Regulatory uncertainties and changes in healthcare reimbursement models can adversely impact product demand or pricing power.
  • Execution risks linked to business separation and integration of new partnerships could distract management or generate unforeseen costs.

What to Watch

UpcomingIn the most recent quarter, Becton Dickinson reported strong financial results, with revenues and earnings surpassing analyst estimates.
UpcomingThe company launched several new products, recorded an 11.4% year-over-year growth in adjusted EPS, and witnessed growth across all its business segments, especially BD Medical.
UpcomingA significant partnership announcement involved automating single-cell analysis instruments through collaboration with Opentrons.
ExpectedFor the upcoming quarter, Becton Dickinson is expected to continue focusing on new product rollouts and executing its strategic business separation if conditions remain favorable.

Price Drivers

  • BDX’s stock price is driven mainly by its quarterly earnings performance, revenue growth, and guidance updates, which directly influence investor sentiment.
  • Broader macroeconomic events, such as interest rate changes, global healthcare demand, and tariff or trade policy news, can create market volatility impacting the stock.
  • Sector-specific factors, such as innovation in medical technology, competitive dynamics, and regulatory changes, also weigh heavily.
  • Share buybacks, business separations, and new product launches contribute to the valuation narrative, particularly when revenue or earnings diverge from analyst expectations.

Recent News

  • Recent news highlights several important themes for Becton Dickinson.
  • The company announced a collaboration with Opentrons to automate its single-cell analysis instruments, sparking renewed investor interest and signaling a push into advanced lab technologies.
  • Quarterly results have been mixed but generally positive, with occasional earnings beats but revenue growth concerns leading to significant share price volatility.
  • Several investment funds have cited BD as an attractive value play despite recent stock declines, and analysts remain generally positive about its long-term prospects.

Market Trends

  • The broader medical equipment and healthcare sector is characterized by rapid technological evolution, increased regulatory scrutiny, and rising demand spurred by demographic trends such as an aging population.
  • There is a clear shift toward automation, digital integration, and laboratory innovation, as seen in BD’s recent product and partnership strategies.
  • However, market volatility is exacerbated by macroeconomic issues, including interest rate uncertainty and international trade dynamics.
  • The sector is seeing consolidation among industry players and strong competition from AI-enabled and data-centric healthcare solutions.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on BDX

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@ReaderMed143 2 months ago

Medical Tech Staple $BDX Adds to Dividend Streak

Medical Tech Staple $BDX Adds to Dividend Streak

Becton Dickinson bumped up its payout once more, keeping alive a steady run of reliable returns. This quiet player in med-tech doesn't grab headlines, yet always shows up. 

Instead of flash, it offers stability perfect for those who value predictability. So far, BDX keeps giving solid reasons to stay in conservative portfolios.

avatar
@DamnRay 5 months ago

Becton, Dickinson & Co declares $1.04/share quarterly dividend

Becton, Dickinson & Co declares $1.04/share quarterly dividend

  had announced a quarterly dividend of $1.04 per common share, payable September 30, 2025, to shareholders of record September 8. The company has been doing good in healthcare equipment sector.

avatar
@MoneyMaker23 5 months ago

Becton, Dickinson and Company just declared its dividend

Becton, Dickinson and Company just declared its dividend

which is a medical technology company, just declared a quarterly cash dividend of $1.04 per share, payable on September 30. The company has paid dividends consistently and seems like a good choice in the health sector.

No more topics to show